RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q1 FY23 results · Apr–Jun 2022
RPG Life Sciences reported revenue from operations of ₹128.93 crore (up 19.2% from Q1 FY22) and net profit of ₹18.21 crore (up 34.1% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a standalone basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 128.93 | 108.13 | +19.2% | 103.80 | +24.2% |
| Other income | 1.22 | 0.41 | +197.6% | 1.26 | −3.2% |
| Total income | 130.15 | 108.54 | +19.9% | 105.06 | +23.9% |
| Profit before tax | 25.12 | 19.27 | +30.4% | 10.93 | +129.8% |
| Net profit for the period | 18.21 | 13.58 | +34.1% | 7.52 | +142.2% |
| EPS, basic (₹) | 11.01 | 8.21 | +34.1% | 4.55 | +142.0% |
| Net margin (%) | 14.1 | 12.6 | 7.2 |
Standalone
- Filed with BSE
- 05 Aug 2022, 12:34 IST
- Board meeting
- 02 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE